UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
UroGen Pharma Ltd. reported Q1 2026 financial results with total revenue of $51.0 million, driven by a 109% quarter-over-quarter increase in ZUSDURI revenue to $29.2 million and 7% year-over-year growth in JELMYTO revenue to $21.7 million. The company highlighted expanding commercial adoption of ZUSDURI, the first and only FDA-approved non-surgical…